Can acadexine reduce the morbidity and mortality of coronary artery bypass grafting?

Mar 15, 2021

Leave a message

In order to evaluate the effect and safety of acadesine powder in reducing perioperative all-factor mortality, non-fatal stroke, and severe left ventricular dysfunction (SLVD) within 28 days, Dr. Mark F. Newman, Duke University Medical Center, et al. After conducting an in-depth study, they found that for a population of intermediate to high-risk patients after CABG surgery, acatexine cannot reduce all-factor mortality, non-fatal stroke, or the incidence of SLVD. Related papers were published in the online edition of the international authoritative journal JAMA on July 11, 2012.


Acadesine Powder-Lenutra

 

This randomized, double-blind, placebo-controlled, parallel-group setting trial aims to explore the reduction in the incidence of cardiovascular events in patients undergoing CABG (RED-CABG) surgery by acadesine. The trial was conducted on 300 individuals from 7 countries. The non-emergency department of two medical units, the middle-risk to high-risk patients (mean age, 66 years) of CABG surgery with cardiopulmonary bypass were evaluated. The recruitment of subjects started from May 6, 2009 to July 30, 2010. Participants who met the test conditions were randomly assigned to receive acadesine (0.1 mg/kg per minute for 7 hours) or placebo (both groups were treated with cardioplegia before induction of anesthesia) at a 1:1 ratio. The main observational endpoint of the trial is all-factor death during or within 28 days of CABG operation, non-fatal stroke, or SLVD mechanically assisted event.

 

The results showed that the results of a pre-designated unprofitable analysis showed that the possibility of a statistically significant and effective result was very small. The trial was terminated after the original planned 7500 randomized subject study was completed in 3080 cases. The primary observational endpoint of the placebo group trial was 75 out of 1493 subjects (5.0%), while the acadexine group was 76 out of 1493 subjects (5.1%) (odds ratio, 1.01 [95% CI, 0.73-1.41]). There was no difference in the secondary observation endpoint of the test.

 

The researchers concluded from this that for the intermediate to high-risk patient population after CABG, acatexine cannot reduce all-factor mortality, non-fatal stroke, or the incidence of SLVD.


Send Inquiry